Aegros

As a Biotech, our value is not in physical assets but in the intangible assets generated by our R&D. As intangible assets traditionally sit off-balance sheet, existing financial reports do not provide investors with the tools to evaluate/compare our business with alternative Biotech investments. Working with EverEdge helped us identify and value our intangible assets which, in turn, enabled us to effectively articulate the true value of our company to our existing and potential investors.